Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) Thomas Powles, Dorothee Nickles, Eliezer Van Allen, Colombe Chappey, Wei Zou, Marcin Kowanetz, Edward Kadel, Mitchell Denker, Zachary Boyd, Nicholas Vogelzang, Joseph Kim, Joaquim Bellmunt, Yohann Loriot, Charles G Drake, Carol O’Hear, Marcella Fasso, Priti Hegde, Sanjeev Mariathasan